U.S. markets close in 6 hours 17 minutes
  • S&P 500

    3,399.70
    -1.27 (-0.04%)
     
  • Dow 30

    27,616.19
    -69.19 (-0.25%)
     
  • Nasdaq

    11,407.75
    +48.81 (+0.43%)
     
  • Russell 2000

    1,605.21
    -35.29 (-2.15%)
     
  • Crude Oil

    38.79
    +0.23 (+0.60%)
     
  • Gold

    1,904.20
    -1.50 (-0.08%)
     
  • Silver

    24.31
    -0.11 (-0.45%)
     
  • EUR/USD

    1.1834
    +0.0021 (+0.18%)
     
  • 10-Yr Bond

    0.7860
    -0.0150 (-1.87%)
     
  • GBP/USD

    1.3038
    +0.0017 (+0.13%)
     
  • USD/JPY

    104.6180
    -0.2170 (-0.21%)
     
  • BTC-USD

    13,356.19
    +246.65 (+1.88%)
     
  • CMC Crypto 200

    266.01
    +4.72 (+1.81%)
     
  • FTSE 100

    5,770.95
    -21.06 (-0.36%)
     
  • Nikkei 225

    23,485.80
    -8.54 (-0.04%)
     

Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018

HOUSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, November 15, 2018 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2018 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 8564777. A live audio webcast of the call will also be available on the Events section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369